Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions

DRUG: MK-1092, 4.0 nmol/kg
DRUG: MK-1092, 8.0 nmol/kg
DRUG: MK-1092, 16 nmol/kg
DRUG: MK-1092, 32 nmol/kg
DRUG: MK-1092, 64 nmol/kg
DRUG: Glargine 3.0 nmol/kg
DRUG: Lispro 1.2 nmol/kg
DRUG: Placebo to glargine
DRUG: Placebo to MK-1092
OTHER: Dextrose
BIOLOGICAL: Insulin

Sponsor

Merck Sharp & Dohme LLC